Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOULDER, COLO. , AUG. 25, 2025 /PRNEWSWIRE/ --ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THE COMPANY WILL PRESENT DATA FROM ITS ENABLE PHASE 1A/1B CLINICAL TRIAL OF ELVN-001 IN BOTH AN ORAL AND A POSTER PRESENTATION AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) 2025 ANNUAL MEETING, TAKING PLACE SEPTEMBER 3-6, 2025, AT THE GEORGE R.

ENLIVEN THERAPEUTICS ANNOUNCES ORAL AND POSTER PRESENTATIONS AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) 2025 ANNUAL MEETING

ANNOUNCED POSITIVE DATA FROM THE PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML, REPORTING A CUMULATIVE MMR RATE OF 47% WITH 32% OF PATIENTS ACHIEVING MMR BY 24 WEEKS AND DEMONSTRATING A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS STRONG BALANCE SHEET WITH $ 491 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO THE FIRST HALF OF 2029 BOULDER, COLO. , AUG. 13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE, INCLUDING HIGHLIGHTS OF PIPELINE PROGRESS.

ENLIVEN THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BOULDER, COLO. , JUNE 16, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS UNDERWRITTEN PUBLIC OFFERING OF 9,920,987 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 1,526,250 ADDITIONAL SHARES OF ITS COMMON STOCK, AT A PRICE TO THE PUBLIC OF $19.66 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 1,780,263 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.659 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BOULDER, COLO. , JUNE 13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS PRICED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 8,394,737 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.66 PER SHARE AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,780,263 SHARES OF ENLIVEN'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $19.659 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ENLIVEN'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ENLIVEN THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BOULDER, COLO. , JUNE13, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ENLIVEN'S COMMON STOCK.

ENLIVEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

REPORTED CUMULATIVE MMR RATE OF 47% (25 OF 53) BY 24 WEEKS WITH 32% (13 OF 41) OF PATIENTS ACHIEVING MMR BY 24 WEEKS, WHICH CONTINUES TO COMPARE FAVORABLY TO PRECEDENT PHASE 1 TRIALS OF APPROVED BCR::ABL1 TKIS ELVN-001 CONTINUES TO DEMONSTRATE A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS WITH 90 PATIENTS ENROLLED AND A MEDIAN TREATMENT DURATION OF ~29 WEEKS AT CUTOFF ENLIVEN WILL HOST A WEBCAST AND CONFERENCE CALL TODAY, JUNE 13, AT 1:30 P.M. ET BOULDER, COLO.

ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML AT EHA 2025 CONGRESS

BOULDER,COLO., MAY 22, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: TD COWEN'S 6TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FROM ASCO & EHA FORMAT: FIRESIDE CHATDATE: TUESDAY, MAY 27, 2025 TIME: 1:00 P.M.

ENLIVEN THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

UPDATED DATA FROM THE PHASE 1 ENABLE CLINICAL TRIAL OF ELVN-001 IN CML TO BE PRESENTED AT THE EHA 2025 CONGRESS IN JUNE EHA ABSTRACT REPORTED CUMULATIVE MMR RATE OF 44% (16 OF 36) BY 24 WEEKS WITH 26% (7 OF 27) OF PATIENTS ACHIEVING MMR BY 24 WEEKS, AND ELVN-001 REMAINS WELL-TOLERATED WITH 74 PATIENTS ENROLLED ENLIVEN TO HOST A WEBCAST AND CONFERENCE CALL FOLLOWING THE ORAL PRESENTATION AT EHA ON FRIDAY, JUNE 13, AT 1:30 P.M. ET STRONG BALANCE SHEET WITH $ 290 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES, WHICH IS EXPECTED TO PROVIDE CASH RUNWAY INTO LATE 2027 BOULDER, COLO.

ENLIVEN THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

REPORTED CUMULATIVE MMR RATE OF 44% (16 OF 36) BY 24 WEEKS WITH 26% (7 OF 27) OF PATIENTS ACHIEVING MMR BY 24 WEEKS, WHICH CONTINUES TO COMPARE FAVORABLY TO PRECEDENT PHASE 1 TRIALS OF APPROVED BCR::ABL1 TKIS ELVN-001 CONTINUES TO DEMONSTRATE A FAVORABLE SAFETY AND TOLERABILITY PROFILE ACROSS ALL DOSE LEVELS WITH 74 PATIENTS ENROLLED AND A MEDIAN TREATMENT DURATION OF ~26 WEEKS AT CUTOFF PRESENTATION AT EHA WILL INCLUDE UPDATED DATA WITH ADDITIONAL PATIENTS AND LONGER TREATMENT DURATION ENLIVEN WILL HOST A WEBCAST AND CONFERENCE CALL ON JUNE 13 AT 1:30 P.M. ET BOULDER, COLO.

ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML AND ORAL PRESENTATION AT THE EHA 2025 CONGRESS

BOULDER, COLO. , APRIL 2, 2025 /PRNEWSWIRE/ -- ENLIVEN THERAPEUTICS, INC. (ENLIVEN OR THE COMPANY) (NASDAQ: ELVN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS, TODAY ANNOUNCED THE COMPANY WILL PRESENT FIVE POSTERS AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, TAKING PLACE APRIL 25-30, 2025, IN CHICAGO, ILLINOIS.

Enliven Therapeutics, Inc.

ELVN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Enliven Therapeutics, Inc.

ELVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ELVN